Perioperative Safety, Surgical Morbidity, and Survival Outcomes of Neoadjuvant Chemotherapy (NACT-IDS) versus Primary Debulking Surgery (PDS) in Elderly Patients with Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis

Abstract Background: Advanced epithelial ovarian cancer disproportionately affects older women. While primary debulking surgery (PDS) is the traditional gold standard, it carries substantial morbidity and mortality risks in frail, older patients. Neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) can downstage disease and mitigate these surgical risks, but high-level evidence syntheses specific to geriatric populations remain limited. Methods: This systematic review and meta-analysis adhered to PRISMA 2020 guidelines and was registered on PROSPERO (CRD420261461644). Five electronic databases and ClinicalTrials.gov were searched for comparative studies evaluating NACT-IDS versus PDS in women aged ≥ 70 years (or ≥ 65 years in defined geriatric cohorts) with FIGO Stage IIIC/IV epithelial ovarian cancer. Outcomes were synthesized using random-effects models. Methodological quality was assessed via the ROBINS-I tool, cumulative evidence reliability via Trial Sequential Analysis (TSA), and overall evidence certainty via the GRADE framework. Results: Eleven retrospective cohort studies encompassing over 16,500 older patients met the inclusion criteria. NACT-IDS yielded an 80% reduction in unadjusted 30-day perioperative mortality compared to PDS (RR = 0.20, 95% CI [0.05, 0.89], p = 0.034). Furthermore, NACT-IDS significantly decreased hospital length of stay (MD = -3.12 days, p = 0.0044) and increased the likelihood of complete macroscopic resection (R0 = 0 cm) by 74% (RR = 1.74, 95% CI [1.01, 3.02], p = 0.047). Severe complications (Clavien-Dindo ≥ 3) trended lower with NACT-IDS (RR = 0.38, 95% CI [0.13, 1.08]). Unadjusted overall survival models demonstrated a 13% increased hazard of death for NACT-IDS (HR = 1.13, 95% CI [1.04, 1.23]); however, this primarily reflects profound selection bias (confounding by indication) where the frailest patients were systematically triaged to the NACT-IDS pathway. The overall certainty of evidence was appraised as Very Low. Conclusion: For older women with advanced epithelial ovarian cancer, NACT-IDS significantly improves perioperative safety, accelerates hospital recovery, and maximizes complete resection rates compared to upfront PDS. While retrospective survival data are heavily skewed by channeling bias, NACT-IDS effectively protects physiological reserve and should be strongly considered as the standard initial management strategy for this vulnerable demographic.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-15
DOI
https://doi.org/10.64898/2026.11.12.26367937
Primary Topic
Ovarian cancer diagnosis and treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Perioperative Safety, Surgical Morbidity, and Survival Outcomes of Neoadjuvant Chemotherapy (NACT-IDS) versus Primary Debulking Surgery (PDS) in Elderly Patients with Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis

Shokouh Taghipour Zahir, Amirhossein Rafiee, Mohammad Ali Boroumand
medRxiv
Ovarian cancer diagnosis and treatment
preprint

Perioperative Safety, Surgical Morbidity, and Survival Outcomes of Neoadjuvant Chemotherapy (NACT-IDS) versus Primary Debulking Surgery (PDS) in Elderly Patients with Advanced Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis

Shokouh Taghipour Zahir, Amirhossein Rafiee, Mohammad Ali Boroumand
preprint en

Abstract

Abstract Background: Advanced epithelial ovarian cancer disproportionately affects older women. While primary debulking surgery (PDS) is the traditional gold standard, it carries substantial morbidity and mortality risks in frail, older patients. Neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) can downstage disease and mitigate these surgical risks, but high-level evidence syntheses specific to geriatric populations remain limited. Methods: This systematic review and meta-analysis adhered to PRISMA 2020 guidelines and was registered on PROSPERO (CRD420261461644). Five electronic databases and ClinicalTrials.gov were searched for comparative studies evaluating NACT-IDS versus PDS in women aged ≥ 70 years (or ≥ 65 years in defined geriatric cohorts) with FIGO Stage IIIC/IV epithelial ovarian cancer. Outcomes were synthesized using random-effects models. Methodological quality was assessed via the ROBINS-I tool, cumulative evidence reliability via Trial Sequential Analysis (TSA), and overall evidence certainty via the GRADE framework. Results: Eleven retrospective cohort studies encompassing over 16,500 older patients met the inclusion criteria. NACT-IDS yielded an 80% reduction in unadjusted 30-day perioperative mortality compared to PDS (RR = 0.20, 95% CI [0.05, 0.89], p = 0.034). Furthermore, NACT-IDS significantly decreased hospital length of stay (MD = -3.12 days, p = 0.0044) and increased the likelihood of complete macroscopic resection (R0 = 0 cm) by 74% (RR = 1.74, 95% CI [1.01, 3.02], p = 0.047). Severe complications (Clavien-Dindo ≥ 3) trended lower with NACT-IDS (RR = 0.38, 95% CI [0.13, 1.08]). Unadjusted overall survival models demonstrated a 13% increased hazard of death for NACT-IDS (HR = 1.13, 95% CI [1.04, 1.23]); however, this primarily reflects profound selection bias (confounding by indication) where the frailest patients were systematically triaged to the NACT-IDS pathway. The overall certainty of evidence was appraised as Very Low. Conclusion: For older women with advanced epithelial ovarian cancer, NACT-IDS significantly improves perioperative safety, accelerates hospital recovery, and maximizes complete resection rates compared to upfront PDS. While retrospective survival data are heavily skewed by channeling bias, NACT-IDS effectively protects physiological reserve and should be strongly considered as the standard initial management strategy for this vulnerable demographic.

medRxiv
Shahid Sadoughi University of Medical Sciences and Health Services (IR)
Ovarian cancer diagnosis and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon